AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Also in today’s newsletter, US regulators plan to investigate Microsoft’s cloud business, and Disney-Reliance Indian media giant says TV ‘is not dead’ ...

The global fatty liver treatment market, valued at approximately USD 20 Billion in 2022, is anticipated to witness ...

DCC shares have jumped 17% in the FTSE 100 index after the Dublin-based conglomerate announced plans to focus on its energy ...

The headline equity benchmarks continued their downward trend on Thursday, marking the sixth consecutive day of losses. The Nifty 50 index settled below the 23,550 mark, having reached a days high of ...

Shares in European vaccine-makers fell in early trade on Friday after U.S. President-elect Donald Trump said he had selected ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Investing.com-- Most Asian currencies moved little on Friday and were nursing losses for the week, while the dollar steadied ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Stocks slid on Thursday as Fed Chair Jerome Powell signaled that policymakers don't need to be in a hurry to cut rates.

Merck on Thursday said it has secured an exclusive global license to develop, manufacture and commercialize LM-299, an investigational PD-1/VEGF bispecific antibody from Shanghai-based LaNova that is ...

AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AZN ...